Why did Astrana Health (ASTH) stock move recently?

On 7/27/2026, Astrana Health moved -6.8% — No company-specific news, earnings, or filing appears to have driven the move; ASTH declined with broader sector or market pressures. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Astrana Health (ASTH) overvalued or fairly valued?

MarketChacha shows Astrana Health's valuation in context — a trailing P/E of about 43.2, a forward P/E of about 10.7, a price-to-book of about 2.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Astrana Health's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.86×) from reported figures — education, not a rating.

What is Astrana Health's revenue?

Astrana Health reported revenue of $3.2B for FY2025, with net profit of $22.5M, per official filings.

What is the share price of Astrana Health (ASTH)?

Astrana Health last traded at $38.47 (+1.7% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Astrana Health

ASTH · NYSE · Healthcare · United States

Snapshot

TickerASTH

ExchangeNYSE

SectorHealthcare

IndustryMedical Care Facilities

CountryUnited States

Employees3,000

HeadquartersAlhambra, United States

Websitewww.astranahealth.com

Filings tracked19

About Astrana Health

Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.

Who owns it

Insiders22.8%
Institutions66.2%
Public & other11.0%

295 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.19.27%
Vanguard Portfolio Management LLC7.28%
Vanguard Capital Management LLC5.44%
State Street Corporation4.86%
325 Capital Llc4.51%
Dimensional Fund Advisors LP4.10%
Wellington Management Group, LLP3.61%
Geode Capital Management, LLC3.26%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 3.7 points over the period — profitability is trending down.

Cash conversion1.86×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend4.4% → 0.7%

Margin has compressed by about 3.7 points over the period — profitability is trending down.

Return on equity2.9%

Latest ROE of 2.9% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 51% · PAT -39%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.0B · EPS 0.64

Est. earnings growth +50.8%

Next fiscal year

Rev $4.4B · EPS 3.54

Est. earnings growth +16.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$3.2B

Net margin

0.7%

ROE

2.9%

Revenue CAGR (2y)

+51.5%

Profit CAGR (2y)

-39.1%

EPS (FY2025)

0.46

Net profit (FY2025)

$22.5M

Ask MarketChacha about ASTH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 27, 2026
No company-specific news, earnings, or filing appears to have driven the move; ASTH declined with broader sector or market pressures.
· confidence: low
Jul 22, 2026
No company-specific catalyst found in filings or credible coverage; ASTH moved lower with the broader market or sector.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$3.2B	$22.5M	0.46	0.7%	2.9%
FY2024	$2.0B	$43.1M	0.90	2.1%	6.1%
FY2023	$1.4B	$60.7M	1.29	4.4%	9.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$972.5M	$19.7M	0.40	2.0%
2026Q1	$965.1M	$14.4M	0.29	1.5%
2025Q3	$956.0M	$373,000	0.01	0.0%
2025Q2	$654.8M	$9.4M	0.19	1.4%
2025Q1	$620.4M	$6.7M	0.14	1.1%
2024Q3	$478.7M	$16.1M	0.33	3.4%
2024Q2	$486.3M	$19.2M	0.40	3.9%
2024Q1	$404.4M	$14.8M	0.31	3.7%
2023Q3	$348.2M	$22.1M	0.47	6.3%
2023Q2	$348.2M	$13.2M	0.28	3.8%
2023Q1	$337.2M	$13.1M	0.28	3.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/10/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/6/2026material
8-K — Reg FD disclosure, Exhibits
SEC7/13/2026material
8-K — Executive/director change
SEC7/1/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC6/10/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/12/2026material
8-K — Executive/director change
SEC5/12/2026material
10-Q filing
SEC5/8/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/7/2026material
8-K — Other events, Exhibits
SEC3/30/2026material
10-K filing
SEC3/12/2026
8-K — Reg FD disclosure, Exhibits
SEC3/4/2026material
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC3/2/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

10-Q filing
SEC11/10/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/6/2025material
8-K/A — Exhibits
SEC9/11/2025
8-K — Results of operations, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.